+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multiple Myeloma Drug Market by Drug Class, Line Of Therapy, Treatment Regimen, Route Of Administration, Patient Age, Gender, Distribution Channel - Global Forecast 2025-2030- Product Image
Multiple Myeloma Drug Market by Drug Class, Line Of Therapy, Treatment Regimen, Route Of Administration, Patient Age, Gender, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Multiple Myeloma Drug Market by Drug Class, Line Of Therapy, Treatment Regimen, Route Of Administration, Patient Age, Gender, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968786
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The multiple myeloma drug market is entering a new era shaped by advanced therapies, increasingly complex treatment pathways, and mounting regulatory considerations. As breakthrough developments reshape clinical practice and supply chains experience pressure, executives require actionable insights for confident decision-making and sustainable portfolio growth.

Market Snapshot: Multiple Myeloma Drug Market

The Multiple Myeloma Drug Market grew from USD 24.51 billion in 2024 to USD 26.52 billion in 2025. It is expected to continue growing at a CAGR of 8.07%, reaching USD 39.05 billion by 2030. These figures underscore market momentum as evolving therapies and care models redefine value within hematology-oncology.

Scope & Segmentation

  • Therapeutic Classes: Histone deacetylase inhibitors (panobinostat), immunomodulatory agents (lenalidomide, pomalidomide, thalidomide), monoclonal antibodies (daratumumab, elotuzumab, isatuximab), proteasome inhibitors (bortezomib, carfilzomib, ixazomib)
  • Line of Therapy: First line, second line, third and subsequent lines, including transitions from doublet to triplet and quadruplet regimens
  • Treatment Regimens: Combination therapy (doublet, triplet, quadruplet), monotherapy
  • Route of Administration: Intravenous, oral, subcutaneous
  • Patient Demographics: Sixty and above, under sixty, female, male
  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy
  • Geographic Coverage: Americas (with coverage of United States states and key markets), Europe, Middle East & Africa (including UK, Germany, France, selected Gulf and African states), and Asia-Pacific (notably China, India, Japan, Southeast Asia, and Australia)
  • Company Analysis: Profiles of Bristol-Myers Squibb Company, Janssen Biotech, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Novartis International AG, AbbVie Inc., Sanofi S.A., GlaxoSmithKline plc, Karyopharm Therapeutics Inc., and Teva Pharmaceutical Industries Ltd.

Key Takeaways for Decision-Makers

  • Multiple myeloma is being managed with a broad portfolio of targeted drugs, raising treatment complexity and options.
  • Combination therapies—especially triplet and quadruplet regimens—are increasingly preferred in later lines of therapy for improved outcomes.
  • Immunomodulatory agents and monoclonal antibodies continue to shift treatment protocols, with new sequencing strategies and expanded use in real-world practice.
  • Patient stratification by cytogenetic risk and the growing use of digital health solutions are influencing prescribing and monitoring adaptations across regions.
  • Manufacturers must continually adapt to evolving reimbursement structures, especially as value-based contracting gains traction in major markets.
  • Distribution is evolving, with online fulfillment channels gaining share alongside traditional hospitals and retail pharmacies.

Tariff Impact and Supply Chain Considerations

Forthcoming tariff adjustments in the United States are expected to introduce new challenges in the multiple myeloma drug supply chain. Key active pharmaceutical ingredients and formulations often depend on international manufacturing, which may increase costs and margin pressure for stakeholders. In response, companies are exploring near-shoring, leveraging free trade agreements, and seeking tariff exemptions for critical therapies. Clear communication and robust inventory strategies are crucial for maintaining uninterrupted patient access in this shifting environment.

Methodology & Data Sources

This report relies on a blended methodology combining secondary data analysis—drawing from peer-reviewed publications, clinical trial registries, regulatory filings, and industry white papers—with primary research through interviews with oncologists, pharmacy directors, regulatory experts, and payers. Every data point is validated for accuracy by triangulating expert insights with real-world evidence, ensuring the most relevant and actionable view of multiple myeloma drug market trends.

Why This Report Matters

  • Senior leaders can benchmark emerging therapeutic strategies and navigate evolving market access frameworks for better decision-making.
  • Commercial teams will understand segmentation patterns and technology adoption drivers across key geographies.
  • Portfolio managers gain clarity on both present and future opportunities amid innovation, policy changes, and supply chain variables.

Conclusion

The multiple myeloma drug market stands at a crossroads, shaped by scientific advancement, new policy landscapes, and shifting commercial realities. Strategic adaptation, collaboration, and data-driven decisions are essential for sustained growth and patient-focused value.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing clinical adoption of BCMA-directed CAR T-cell therapies in relapsed refractory multiple myeloma patients
5.2. Expansion of oral proteasome inhibitor combination regimens improving frontline multiple myeloma treatment outcomes
5.3. Emergence of next-generation cereblon E3 ligase modulators enhancing response rates in multiple myeloma
5.4. Implementation of personalized minimal residual disease monitoring to guide therapy adjustments in multiple myeloma
5.5. Development of bispecific antibody platforms targeting multiple myeloma surface antigens beyond BCMA
5.6. Growing pipeline of antibody-drug conjugates combining novel payloads for targeted multiple myeloma therapy
5.7. Use of real-world evidence to support regulatory approvals and market access for multiple myeloma therapies
5.8. Integration of advanced imaging and liquid biopsy biomarkers for early detection of multiple myeloma relapse
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Multiple Myeloma Drug Market, by Drug Class
8.1. Introduction
8.2. Histone Deacetylase Inhibitors
8.2.1. Panobinostat
8.3. Immunomodulatory Agents
8.3.1. Lenalidomide
8.3.2. Pomalidomide
8.3.3. Thalidomide
8.4. Monoclonal Antibodies
8.4.1. Daratumumab
8.4.2. Elotuzumab
8.4.3. Isatuximab
8.5. Proteasome Inhibitors
8.5.1. Bortezomib
8.5.2. Carfilzomib
8.5.3. Ixazomib
9. Multiple Myeloma Drug Market, by Line Of Therapy
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third And Beyond
10. Multiple Myeloma Drug Market, by Treatment Regimen
10.1. Introduction
10.2. Combination Therapy
10.2.1. Doublet Regimen
10.2.2. Quadruplet Regimen
10.2.3. Triplet Regimen
10.3. Monotherapy
11. Multiple Myeloma Drug Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Multiple Myeloma Drug Market, by Patient Age
12.1. Introduction
12.2. Sixty And Above
12.3. Under Sixty
13. Multiple Myeloma Drug Market, by Gender
13.1. Introduction
13.2. Female
13.3. Male
14. Multiple Myeloma Drug Market, by Distribution Channel
14.1. Introduction
14.2. Hospital Pharmacy
14.3. Online Pharmacy
14.4. Retail Pharmacy
15. Americas Multiple Myeloma Drug Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Multiple Myeloma Drug Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Multiple Myeloma Drug Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Bristol-Myers Squibb Company
18.3.2. Janssen Biotech, Inc.
18.3.3. Takeda Pharmaceutical Company Limited
18.3.4. Amgen Inc.
18.3.5. Novartis International AG
18.3.6. AbbVie Inc.
18.3.7. Sanofi S.A.
18.3.8. GlaxoSmithKline plc
18.3.9. Karyopharm Therapeutics Inc.
18.3.10. Teva Pharmaceutical Industries Ltd.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. MULTIPLE MYELOMA DRUG MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. MULTIPLE MYELOMA DRUG MARKET: RESEARCHAI
FIGURE 30. MULTIPLE MYELOMA DRUG MARKET: RESEARCHSTATISTICS
FIGURE 31. MULTIPLE MYELOMA DRUG MARKET: RESEARCHCONTACTS
FIGURE 32. MULTIPLE MYELOMA DRUG MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MULTIPLE MYELOMA DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 149. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 150. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 151. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 152. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 153. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 154. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 155. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 156. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 157. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 158. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 159. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 160. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 161. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 162. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 163. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 164. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 165. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 168. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 169. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 170. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 171. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 176. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 177. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 178. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 179. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 180. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 181. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 182. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 183. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 184. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 185. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 186. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 187. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 188. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 189. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 190. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 191. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 192. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 193. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 194. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 195. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 278. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 284. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 296. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 297. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 298. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 299. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 300. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 301. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 302. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 303. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2024 (USD MILLION)
TABLE 304. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2025-2030 (USD MILLION)
TABLE 305. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 306. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 307. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 308. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 309. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 310. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 311. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 312. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 313. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 314. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 315. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 316. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 317. GERMANY M

Samples

Loading
LOADING...

Companies Mentioned

  • Bristol-Myers Squibb Company
  • Janssen Biotech, Inc.
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Novartis International AG
  • AbbVie Inc.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Karyopharm Therapeutics Inc.
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 26.52 Billion
Forecasted Market Value ( USD ) by 2030 $ 39.05 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Multiple Myeloma Drugs Market Report 2025 - Product Image

Multiple Myeloma Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Multiple Myeloma Therapeutics - Global Strategic Business Report - Product Image

Multiple Myeloma Therapeutics - Global Strategic Business Report

  • Report
  • 293 Pages
  • Global
From
Multiple Myeloma Drugs - Global Strategic Business Report - Product Image

Multiple Myeloma Drugs - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From
Multiple Myeloma Drug Pipeline Analysis Report 2025 - Product Image

Multiple Myeloma Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Multiple Myeloma Therapeutics Market by Drug Class (CAR-T Therapy, Histone Deacetylase Inhibitor, Immunomodulatory Drug), Mode Of Administration (Intravenous, Oral, Subcutaneous), Distribution Channel, Product Type - Global Forecast 2025-2030 - Product Image

Multiple Myeloma Therapeutics Market by Drug Class (CAR-T Therapy, Histone Deacetylase Inhibitor, Immunomodulatory Drug), Mode Of Administration (Intravenous, Oral, Subcutaneous), Distribution Channel, Product Type - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From

About the Multiple Myeloma Drug Market

Multiple Myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is a form of Leukemia, and is the second most common type of blood cancer. Treatment for Multiple Myeloma typically involves a combination of chemotherapy, radiation therapy, and targeted drug therapy. The Multiple Myeloma drug market is composed of a variety of drugs, including proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and other targeted therapies. These drugs are used to treat the disease, as well as to reduce the risk of relapse. The Multiple Myeloma drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include Bristol-Myers Squibb, Celgene, Novartis, Amgen, and Johnson & Johnson. Other companies such as Merck, Pfizer, and Takeda are also active in the market. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.